Peptides: precision is something to demonstrate
In this investigation
- Four separate questions behind the word precise
- Injection changes the route, not the destination
- Oral peptides are possible; the formulation does the work
- Biological familiarity does not erase immune responses
- Approval, compounding and registration answer different questions
- How this changes my research priorities
I initially pictured peptides as specialized amino-acid chains that could be delivered exactly where needed, with almost any biological function designed into them. The interesting part of that picture is real: amino-acid sequence and formulation can change a drug’s behavior. The leap from a plausible sequence to reliable control of a human body is much larger.
Four separate questions behind the word precise
| Question | What would establish it? | What does not establish it? |
|---|---|---|
| Does it bind the intended target? | Experiments measuring binding and activity, including other relevant targets | A proposed mechanism or an attractive molecular diagram |
| Does enough active material reach the relevant tissue? | Validated measurements of exposure, distribution and persistence | The amount put in a vial or the fact that it was injected |
| Does target engagement improve the desired outcome? | Controlled human outcomes such as function, symptoms or events | A changed hormone concentration alone |
| Is the tradeoff acceptable? | Appropriate monitoring, comparators and sufficiently long follow-up | No side effects reported by a few people |
These questions are a reading framework, not a requirement that every early experiment answer everything. A good early study can establish one step while leaving the next open. Problems arise when all four are collapsed into a single claim that a peptide works.
Injection changes the route, not the destination
Intravenous administration places material in the circulation. Subcutaneous administration first requires absorption from tissue. Neither, by itself, provides an address label for an injured tendon or a particular muscle. Distribution, degradation, clearance and the location of responsive cells still matter. Target selectivity and tissue selectivity are different claims.
FDA’s peptide-development draft describes structural modifications and formulation strategies intended to improve absorption, distribution, metabolism and excretion. It also calls for assessments of immunogenicity and exposure relationships. Those are development problems to solve and measure, not properties bestowed by calling a substance a peptide. The document is draft, nonbinding guidance, not an approval of any particular compound. FDA peptide clinical-pharmacology draft
Oral peptides are possible; the formulation does the work
Semaglutide is a useful counterexample to the idea that peptides must always be injected. Its oral formulation uses the absorption enhancer SNAC. In a randomized crossover experiment, 27 healthy men were randomized and 26 received the study product. Investigators imaged tablet erosion and measured blood concentrations; the tablets eroded in the stomach. Another original development study connected gastric absorption to the coformulation. These are specific formulation findings, not evidence that arbitrary peptide capsules are absorbed intact. Human pharmacoscintigraphy study, Original absorption research
The FDA-approved semaglutide product illustrates another distinction: approval concerns a defined product and intended uses. FDA’s 2025 approval report includes an oral Wegovy formulation. That does not transfer its evidence to an unrelated molecule or to an unverified product sold under a familiar peptide name. FDA’s 2025 new-therapy report
Biological familiarity does not erase immune responses
A sequence related to a human molecule can still produce an unwanted immune response. Antibodies may bind a therapeutic product, reduce its effect or produce adverse reactions. The likelihood depends on the product and patient; it should be measured rather than presumed. FDA’s immunogenicity guidance explicitly treats the assessment as case specific. FDA immunogenicity guidance
That is different from saying every peptide is highly immunogenic. The peptide draft notes that very short peptides are generally less likely to be immunogenic, while impurities or aggregates can change the assessment. A short amino-acid chain, its copper complex, an acetylated fragment and a mixture of several chains are also distinct exposures. Their safety evidence is not automatically interchangeable. FDA peptide clinical-pharmacology draft
Approval, compounding and registration answer different questions
An approved drug has undergone a product-specific assessment. A compounded drug has not received FDA approval; compounding can serve particular medical needs, but it does not provide the same premarket verification of effectiveness, safety and quality. Poor preparation can introduce contamination or incorrect potency. FDA compounding questions and answers
Orphan-drug designation is a development incentive, separate from approval. A trial registration records a submitted study plan, not successful results. Even a well-designed protocol cannot be counted as demonstrated benefit before the trial is completed and its findings examined. FDA orphan-product designation
How this changes my research priorities
For my current question about training and recovery, the outcome of interest is durable comfort and function, with a diagnosis and appropriate loading plan where needed. A favorable cellular signal, increased IGF-1 or a changed body-composition scan would answer a narrower question. The recovery investigation and nutrient guide cover the foundations alongside this experimental research.
The frontier is worth following. The useful next claim is specific: this exact intervention, in this population, improved this measured outcome over this comparator, with these limits. That sentence leaves room for promising early work while making exaggerated precision easier to spot.